Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus CNCM I-3690
- Development stage
- Unknown
- Lead developer
- Danone
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus CNCM I-3690 is a specific probiotic bacterial strain isolated and characterized as Collection Nationale de Cultures de Microorganismes (CNCM) I-3690. It is noted for its ability to restore and maintain intestinal barrier function through both **anti-inflammatory** and **cytoprotective** activities, including the stimulation of mucus production and restoration of tight junction proteins (occludin, E-cadherin) in the gut epithelium[1][2][3]. CNCM I-3690 can modulate the immune response, increase goblet cell numbers, and reduce gut permeability in animal models and healthy humans subjected to stress-induced barrier dysfunction, showing potential for alleviating low-grade inflammation associated with conditions such as irritable bowel syndrome or inflammatory bowel disease[2][4]. It is regarded as a live biotherapeutic product and belongs to the broader class of microbial therapies.
- Other names
- Lactobacillus rhamnosus strain CNCM I-3690
Beyond the preview
Go deeper on lactobacillus rhamnosus CNCM I-3690.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus CNCM I-3690.